Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
Patients with metastatic castration-resistant prostate cancer (mCRPC) are divided into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. In the latter two groups, successful outcomes may not be achieved due to the development of drug-resista...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science (PLoS)
2023-01-01
|
| Col·lecció: | PLoS ONE |
| Accés en línia: | https://doi.org/10.1371/journal.pone.0282646 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|